A Phase 3 interventional study of Dabigatran Etexilate 110mg and Warfarin 3mg in Atrial Fibrillation and Percutaneous Coronary Intervention, sponsored by Boehringer Ingelheim. Completed at 421 sites in 41 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.
Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 2nd largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 3, and was the 17th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 22
First in 2003; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,725 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 174 across the 35 interventional studies. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 35 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
45 studies in Atrial Fibrillation by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 45 finished, 44 (98%) have results posted.
Among the 45 studies in Atrial Fibrillation by Boehringer Ingelheim, this one is one of 8 that started in 2014, is one of 3 in phase 3, and was the 22nd registered.
Boehringer Ingelheim’s Atrial Fibrillation studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 35 studies testing dabigatran in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 45 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (150mg DE-DAT) with a Triple Antithrombotic Therapy (TAT) combination of warfarin plus clopidogrel or ticagrelor plus Aspirin (ASA) \<= 100mg once daily (warfarin-TAT) in patients with Atrial Fibrillation that undergo a PCI with stenting (elective or due to an Acute Coronary Syndrome).
The study aims to show non-inferiority of each dose of DE-DAT when compared to Warfarin-TAT in terms of safety. Safety will be determined by comparing the rates of bleeding events, assessed using the modified International Society of Thrombosis and Haemostasis classification of Major Bleeding and Clinically Relevant Non Major Bleeding Events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An Acute Coronary Syndrome (ACS) (ST elevation myocardial infarction (STEMI), NonSTEMI [NSTEMI] or unstable angina [UA]) that was successfully treated by PCI and stenting (either Bare Metal Stent (BMS) or Drug Eluting Stent) Or Stable Coronary Artery Disease with at least one lesion eligible for PCI that was successfully treated by elective PCI and stenting (either BMS or DES)
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
Drug: Dabigatran Etexilate 110mg · Drug: Clopidogrel or Ticagrelor
Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
Drug: Dabigatran Etexilate 150mg · Drug: Clopidogrel or Ticagrelor
Warfarin doses to maintain INR
Drug: Warfarin 3mg · Drug: Aspirin · Drug: Clopidogrel or Ticagrelor · Drug: Warfarin 5mg · Drug: Warfarin 1mg
Active treatment
Active comparator
Active comparator
Active treatment
Active comparator
Active comparator
Active comparator
Active comparator
Active comparator
Time to First Adjudicated ISTH MBE or CRNMBE
Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported. Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial. Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status. Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.
Time frame: up to 30 months
Time to Adjudicated Undetermined Cause of Death
Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported. This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was "patient died") or when there was insufficient supporting information or detail to assign the cause of death.
Time frame: up to 30 months
Time to Adjudicated Non-CV
Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported. Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV
Time frame: up to 30 months
Time to Adjudicated CV
Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported. CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.
Time frame: up to 30 months
Time to Adjudicated All Cause Death
Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.
Time frame: up to 30 months
Time to First Adjudicated MI
Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported
Time frame: up to 30 months
Time to First Adjudicated Stroke
Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction
Time frame: up to 30 months
Time to First Adjudicated SE
Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported. SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.
Time frame: up to 30 months
Time to First Adjudicated ST
Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.
Time frame: up to 30 months
Time to Composite Endpoint of Death + MI + Stroke
Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.
Time frame: up to 30 months
Time to Composite Endpoint of Death or First Thrombotic Event
Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).
Time frame: up to 30 months
Time to First Adjudicated Unplanned Revascularisation by PCI/CABG
Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.
Time frame: up to 30 months
Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG
Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.
Time frame: up to 30 months
Patients aged ≥80 years in the United States of America (USA) were assigned to 110 milligram (mg) Dual antithrombotic therapy with dabigatran etexilate (DE-DAT), 150 mg DE-DAT, or warfarin. All other patients including aged ≥80 years (for Japan ≥70 years) outside of the USA were assigned to 110 mg DE-DAT or warfarin
| Milestone | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin |
|---|---|---|---|
| Started | 981 | 763 | 981 |
| Completed | 886 | 703 | 849 |
| Not completed | 95 | 60 | 132 |
| Withdrew: Trial disease worsening | 7 | 5 | 1 |
| Withdrew: Other pre-existing disease worsening | 6 | 4 | 9 |
| Withdrew: Other adverse event (ae) | 52 | 32 | 49 |
| Withdrew: Protocol violation | 2 | 4 | 1 |
| Withdrew: Lost to follow-up | 4 | 3 | 2 |
| Withdrew: Consent withdrawn, not due to ae | 21 | 8 | 56 |
| Withdrew: Other than stated | 3 | 4 | 14 |
Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported. Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial. Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status. Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to First Adjudicated ISTH MBE or CRNMBE | 151 | 154 | 264 | 196 |
Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported. This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was "patient died") or when there was insufficient supporting information or detail to assign the cause of death.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to Adjudicated Undetermined Cause of Death | 4 | 5 | 4 | 3 |
Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported. Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to Adjudicated Non-CV | 14 | 4 | 13 | 8 |
Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported. CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to Adjudicated CV | 37 | 21 | 31 | 24 |
Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to Adjudicated All Cause Death | 55 | 30 | 48 | 35 |
Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to First Adjudicated MI | 44 | 26 | 29 | 22 |
Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to First Adjudicated Stroke | 17 | 9 | 13 | 8 |
Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported. SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to First Adjudicated SE | 3 | 1 | 3 | 3 |
Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to First Adjudicated ST | 15 | 7 | 8 | 7 |
Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to Composite Endpoint of Death + MI + Stroke | 107 | 60 | 80 | 57 |
Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA | All Dabigatran Etexilate |
|---|---|---|---|---|---|
| Time to Composite Endpoint of Death or First Thrombotic Event | 108 | 60 | 83 | 60 | 168 |
Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) |
|---|---|---|---|---|
| Time to First Adjudicated Unplanned Revascularisation by PCI/CABG | 76 | 51 | 69 | 52 |
Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.
| Participants | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Warfarin (Excluding Elder Patients Outside USA) | All Dabigatran Etexilate |
|---|---|---|---|---|---|
| Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG | 149 | 90 | 131 | 98 | 239 |
Collected over From the first intake of randomised trial drug until 6 days after the last intake of the randomised trial drug, ie., up to 31 Months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate 110mg | 38/972 (3.9%) | 415/972 (42.7%) | 128/972 (13.2%) |
| Dabigatran Etexilate 150mg | 24/758 (3.2%) | 300/758 (39.6%) | 126/758 (16.6%) |
| Warfarin | 41/948 (4.3%) | 396/948 (41.8%) | 229/948 (24.2%) |
| Event | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin |
|---|---|---|---|
| Cardiac failureCardiac disorders | 48/972 | 30/758 | 46/948 |
| Atrial fibrillationCardiac disorders | 44/972 | 36/758 | 34/948 |
| Angina unstableCardiac disorders | 26/972 | 15/758 | 13/948 |
| Vascular stent thrombosisGeneral disorders | 25/972 | 10/758 | 17/948 |
| Angina pectorisCardiac disorders | 20/972 | 18/758 | 18/948 |
| Acute myocardial infarctionCardiac disorders | 20/972 | 14/758 | 15/948 |
| PneumoniaInfections and infestations | 20/972 | 15/758 | 19/948 |
| Cardiac failure congestiveCardiac disorders | 14/972 | 13/758 | 19/948 |
| Chest painGeneral disorders | 14/972 | 15/758 | 15/948 |
| Atrial flutterCardiac disorders | 18/972 | 8/758 | 6/948 |
| Event | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 52/972 | 59/758 | 146/948 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 62/972 | 60/758 | 61/948 |
| HaematomaVascular disorders | 27/972 | 24/758 | 60/948 |
The anaysis set used was Full analysis set (FAS)
| Age, Continuous(Years) | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Total |
|---|---|---|---|---|
| Mean | 71.5 ± 8.87 | 68.6 ± 7.65 | 71.7 ± 8.90 | 70.8 ± 8.66 |
| Age, Customized(Participants) | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Total |
|---|---|---|---|---|
| <80: EU/ROW | 725 | 699 | 718 | 2142 |
| <80: USA | 54 | 53 | 61 | 168 |
| ≥80: EU/ROW | 189 | 3 | 192 | 384 |
| ≥80: USA | 13 | 8 | 10 | 31 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Total |
|---|---|---|---|---|
| Female | 253 | 171 | 231 | 655 |
| Male | 728 | 592 | 750 | 2070 |
| Ethnicity (NIH/OMB)(Participants) | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Total |
|---|---|---|---|---|
| Hispanic or Latino | 70 | 46 | 59 | 175 |
| Not Hispanic or Latino | 903 | 700 | 904 | 2507 |
| Unknown or Not Reported | 8 | 17 | 18 | 43 |
| Race/Ethnicity, Customized(Participants) | Dabigatran Etexilate 110mg | Dabigatran Etexilate 150mg | Warfarin | Total |
|---|---|---|---|---|
| Asian | 116 | 79 | 125 | 320 |
| Black | 5 | 7 | 3 | 15 |
| White | 851 | 658 | 835 | 2344 |
| Other | 5 | 8 | 7 | 20 |
| Missing | 4 | 11 | 11 | 26 |
Showing the first 100 of 421 sites across 41 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2014 to primary completion in Jun 2017, 34 months.
Results were first posted in Jul 2018, 1 year 1 month after primary completion.
Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran